Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021
-
- Saeki Hidehisa
- Department of Dermatology, Nippon Medical School
-
- Ohya Yukihiro
- Allergy Center, National Center for Child Health and Development
-
- Furuta Junichi
- Medical Informatics and Management, Faculty of Medicine, University of Tsukuba
-
- Arakawa Hirokazu
- Kitakanto Allergy Research Institute, Kibounoie Hospital
-
- Ichiyama Susumu
- Department of Dermatology, Nippon Medical School
-
- Katsunuma Toshio
- Department of Pediatrics, The Jikei University Daisan Hospital
-
- Katoh Norito
- Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science
-
- Tanaka Akio
- Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University
-
- Tsunemi Yuichiro
- Department of Dermatology, Saitama Medical University
-
- Nakahara Takeshi
- Department of Dermatology, Graduate School of Medical Sciences, Kyushu University
-
- Nagao Mizuho
- Allergy Center, National Hospital Organization Mie National Hospital
-
- Narita Masami
- Department of Pediatrics, Faculty of Medicine, Kyorin University
-
- Hide Michihiro
- Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University Department of Dermatology, Hiroshima Citizens Hospital
-
- Fujisawa Takao
- Allergy Center, National Hospital Organization Mie National Hospital
-
- Futamura Masaki
- Division of Pediatrics, National Hospital Organization Nagoya Medical Center
-
- Masuda Koji
- Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science
-
- Matsubara Tomoyo
- Department of Pediatrics, Dokkyo Medical University Saitama Medical Center
-
- Murota Hiroyuki
- Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences
-
- Yamamoto-Hanada Kiwako
- Allergy Center, National Center for Child Health and Development
Search this article
Description
<p>This is an abridged edition of English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. In Japan, from the perspective of evidence-based medicine, the current strategies for the treatment of AD consist of three primary measures: (i) use of topical corticosteroids, tacrolimus ointment, and delgocitinib ointment as the main treatment of the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling, and advice about daily life. In the present revised guidelines, the description about three new drugs, namely, dupilumab, delgocitinib, and baricitinib, has been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.</p>
Journal
-
- Allergology International
-
Allergology International 71 (4), 448-458, 2022
Japanese Society of Allergology
